Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. (AMGN) is a global biotechnology leader pioneering innovative therapies for serious illnesses. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's latest developments, regulatory milestones, and strategic initiatives.
Track critical updates across Amgen's core therapeutic areas including oncology treatments, inflammatory disease therapies, and rare disease solutions. Our curated feed includes earnings reports, clinical trial data, partnership announcements, and manufacturing updates - all sourced directly from official channels.
Key resources include timely coverage of FDA decisions, research breakthroughs in biologics and biosimilars, and analysis of market-moving events. Bookmark this page for structured access to Amgen's evolving pipeline and business strategies without promotional bias.
Amgen announced positive Phase 2 results for sotorasib, a KRAS G12C inhibitor, in treating advanced non-small cell lung cancer (NSCLC) in patients with prior treatment failures. The study involved 126 patients, showing an objective response rate consistent with past Phase 1 data and promising efficacy measures. More than half of responders remained on treatment at data cutoff. Amgen plans to discuss results with regulatory agencies and is advancing its development program, which includes a Phase 3 study, CodeBreaK 200, comparing sotorasib to docetaxel.
Amgen announced positive results for Aimovig (erenumab-aooe) at the Migraine Trust Virtual Symposium, showcasing a five-year study on its safety and efficacy in treating episodic migraine. The Phase 2 study involved 383 patients, with 216 completing the open-label phase. Results indicated a reduction of 5.3 monthly migraine days and 4.4 days less use of acute migraine medication. No increase in adverse events was recorded, affirming Aimovig's safety profile. This long-term data further establishes Aimovig as a leading preventive treatment for migraines.
Amgen announces updated data from the CodeBreaK 100 clinical study on sotorasib, a KRASG12C inhibitor, published in the New England Journal of Medicine. The study evaluated 129 patients across various advanced solid tumors. In 34 heavily pretreated patients with advanced non-small cell lung cancer (NSCLC), sotorasib showed an objective response rate of 35.3% and a disease control rate of 91.2%. Safety data demonstrated tolerability, with no dose-limiting toxicities. Upcoming Phase 2 results are highly anticipated among investors and the medical community.
Amgen will host two webcast investor calls during the ESMO 2020 Virtual Congress. The first call is scheduled for September 20, 2020, at 11:00 a.m. PDT, where Dr. David M. Reese will discuss Phase 1 data on the KRASG12C inhibitor, sotorasib (AMG 510). The second call is on September 21, at 1:00 p.m. PDT, focusing on a bispecific T-cell engager targeting PSMA. These webcasts will be available live and archived on Amgen's website for at least 90 days, making it accessible to investors and the public.
Amgen (NASDAQ:AMGN) announced it will present data from its oncology pipeline during the ESMO Virtual Congress 2020, taking place from Sept. 19-21, 2020. Key presentations include Phase 1 clinical results for AMG 510, a KRASG12C inhibitor for non-small cell lung cancer, and AMG 160, a bispecific T cell engager targeting prostate cancer. Highlights include a presentation on clinical benefit durability for AMG 510 on Sept. 20 and AMG 160 on Sept. 21. The company will also hold webcast calls on Sept. 20 and 21 to discuss Phase 1 data with investors.
Amgen (NASDAQ:AMGN) and MBC BioLabs have awarded the 2020 Amgen Golden Ticket to BigHat Biosciences and Trilo Therapeutics. This grant provides priority lab space and access to core facilities for one year, supporting innovative biotech companies in their research. BigHat focuses on advancing antibody discovery using AI, while Trilo specializes in developing novel therapeutic inhibitors for diseases. Amgen's partnership with MBC BioLabs has expanded from one site to three, benefiting over 90 startups since its inception.
Amgen (NASDAQ:AMGN) will present at the Bank of America Virtual Global Healthcare Conference at 12:35 p.m. ET on Sept. 17, 2020. The presentation will be made by Peter H. Griffith, executive vice president and CFO of Amgen. Interested parties can access the live audio on Amgen's website under the Events Calendar, with replays available for 90 days following the event. Amgen is dedicated to innovative therapeutics to improve health outcomes and has a strong pipeline of medicines aimed at serious illnesses.
Amgen will present at Morgan Stanley's 18th Annual Virtual Global Healthcare Conference on Sept. 16, 2020, at 11:45 a.m. ET. CEO Robert A. Bradway will lead the presentation, which can be accessed live via Amgen's website. A replay will be available for 90 days post-event. Amgen focuses on innovative therapeutics for serious illnesses, leveraging advanced human genetics to improve health outcomes. With a history dating back to 1980, Amgen is a leader in biotechnology.
Amgen will present at Citi's 15th Annual Virtual BioPharma Conference on September 10, 2020, at 2:25 p.m. ET. Key executives, Murdo Gordon and Peter H. Griffith, will deliver the presentation. Interested parties can access live audio via Amgen's website, with a replay available for 90 days post-event. Founded in 1980, Amgen is a leading biotechnology company focused on innovative therapeutics, emphasizing solutions for serious illnesses and unmet medical needs. For more details, visit www.amgen.com.
Amgen announced positive results from the HAUSER-RCT Phase 3b study for Repatha® (evolocumab) in pediatric patients aged 10-17 with heterozygous familial hypercholesterolemia (HeFH). The study demonstrated a significant 38.3% reduction in LDL-C levels compared to placebo, meeting its primary endpoint. It was presented at ESC 2020 and published in The New England Journal of Medicine. No new safety risks were noted, with adverse events being generally mild. The study emphasizes Repatha's potential as a safe and effective option for managing high cholesterol in children.
